Shionogi & Co., Ltd.

Shionogi & Co. faced a decline in stock price amid a challenging trading session, contrasting with the Japan Nikkei 225's performance. Despite recent setbacks, the company has shown resilience with a year-to-date increase and strong financial metrics, including robust EBIT to Interest ratio and record quarterly results.

Shionogi & Co. has shown strong performance in the Pharmaceuticals & Biotechnology sector, with significant gains over various timeframes. The company reported impressive quarterly results, including substantial net sales and operating profit, while maintaining a robust EBIT to Interest ratio, reflecting effective debt management and a solid market position.

Shionogi & Co. saw a decline in its stock price amid broader market trends, with the Japan Nikkei 225 index also falling. Despite recent fluctuations, the company has shown resilience with a year-to-date performance exceeding the index. Shionogi's financial health remains strong, supported by solid quarterly results.

Shionogi & Co. saw a decline in its stock price amid broader market trends, with the Japan Nikkei 225 index also falling. Despite recent fluctuations, the company reported strong quarterly results and maintains a solid financial position, highlighted by a healthy EBIT to Interest ratio and significant market capitalization.

Shionogi & Co. faced a significant stock price decline on October 14, 2025, reaching an intraday low. The company's recent performance contrasts with the Japan Nikkei 225, showing a notable decrease over various time frames. Despite this, Shionogi has demonstrated resilience with a positive annual return.

Shionogi & Co. has experienced notable trading activity, with a one-day gain of 3.53% and an intraday high of JPY 2,624.00. The company has shown a year-over-year increase of 24.27%, supported by strong financial metrics, including a robust Return on Equity and a solid EBIT to Interest ratio.

Shionogi & Co. has shown strong market activity, gaining 4.36% on October 6, 2025, with an intraday high of JPY 2,602.50. The company has outperformed the Japan Nikkei 225 over various timeframes and maintains solid financial metrics, including a robust Return on Equity and favorable valuation.